Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.02.03
Silica-induced pulmonary fibrosis model
We would like to introduce you to a Silica-induced pulmonary fibrosis model. This model is suitable for you if you want to evaluate lung fibrosis over a long period of time (e.g. cell therapy) The Silica-induced pulmonary fibrosis model reproduces the pathology of the Silicosis, with the production of reactive oxygen species, cell death…
2025.02.03
In Vitro Assay Service for Fibrosis Evaluation
We are delighted to announce the launch of our new in vitro assay service for fibrosis evaluation. By launching this service, we now offer a cost-effective and efficient way to conduct preliminary studies and screen compounds for potential fibrotic effects, saving valuable time and resources in your drug development journey. This not only…
2025.02.03
STAM mouse | Adiponectin-derived peptide study to inhibit MASH and fibrosis progression
Today, we would like to introduce an example of a proof-of-concept study of adiponectin-derived peptide ALY688 in STAMTM mice, which was published in Clinical and Translational Science by a research team from Allysta Pharmaceuticals, Inc. in the United States. The adiponectin – derived peptide ALY688 protects against the development of metabolic dysfunction-associated steatohepatitis –…
2025.02.03
Lung functional marker in IPF model
We would like to introduce a non-invasive biomarkers for Idiopathic Pulmonary Fibrosis (IPF) disease models. In lung diseases such as idiopathic pulmonary fibrosis, lung function is evaluated along with CT and histopathological analysis of the lung. In the case of mice, evaluation of lung function is not easy to perform due to the complexity…
2025.02.03
Drug efficacy studies in NASH mouse model
Today, we would like to introduce a paper published by our client using our non-alcoholic steatohepatitis (NASH) model. (Yang et al., Int J Biol Sci., 2021). This paper focuses on the prevention of the progression of NASH-derived liver cancer, which has attracted a lot of attention in recent years. After analyzing their target based…
2025.02.03
Preclinical studies for IBD research: DSS model
We would like to introduce the dextran sulfate sodium (DSS) -induced colitis model, which is a clinically representative mouse model that can be used to conduct drug efficacy studies targeting Inflammatory Bowel Disease. This model is widely used to elucidate the mechanism of IBD pathogenesis and evaluate drug candidates because of its rapidity, simplicity…
2025.02.03
Advantages of using multiple MASH models: STAM x GAN diet
Advantages of using multiple MASH models; STAMTM x GAN diet – Comprehensively covers criteria for MASH patients in clinical trials – Using GAN diet with STAMTM comprehensively covers obesity, steatosis score, and fibrosis score Comparison table; STAMTM x GAN diet Several ideal MASH models have been described in the literature, but currently…
2025.02.03
Expanding Our IPF Services: Introducing Male Mouse Models for Drug Efficacy Evaluation Studies
We would like to inform you that we have extended our drug efficacy evaluation study services for male bleomycin (BLM)-induced lung fibrosis mouse model. Idiopathic pulmonary fibrosis (IPF) is a lung disease that causes fibrosis in the lungs, and is more common in men than in women. Until now, we have primarily used female…
2025.02.03
The STAM Model in NASH fundamental research
We would like to share some examples of how our NASH-HCC model (STAMTM model) can be used for fundamental research. NASH is a disease area in which great demand remains in fundamental research such as elucidation of pathogenic mechanisms and development of new diagnostic methods. Fundamental research is often conducted using animal disease…
2025.02.03
RNA sequencing data from STAM mice
We would like to introduce the acquisition of RNA sequencing data from STAMTM mice which we hope to utilize to offer our clients high value proposals. The STAMTM mouse is used as a NASH-HCC model that shows similar pathology to human NASH (fatty liver → NASH → liver fibrosis → HCC), and has been…
We can help you advance your research.